Medicines beyond
Nature
Medicines beyond
Nature
patients and their families
The Pipeline
The Pipeline
Mirror Peptides are synthetic, fully D-amino acid peptides that represent a vast, unexplored chemical space beyond naturally occurring peptides and proteins. Compared to existing modalities, Mirror Peptides provide superior characteristics in therapeutic stability and exogenous immunogenicity that have the potential to improve the safety and efficacy of therapeutics for patients and their families.
Aizen is developing Mirror Peptides as the next-generation targeting and delivery platform for a diverse set of indications.
Discovery
IND-Enabling
Phase 1
The Platform
The Platform
The DaX™ platform, pioneered by Caltech Professor David Van Valen, MD, PhD, is a first-in-class, structure-based protein design model for Mirror Peptides. The platform harnesses advancements in Generative AI to unlock the insights of natural ligand-receptor data sets to build de novo Mirror Peptide structures that bind to clinically-relevant targets. DaX™ leverages the latest methods in guided diffusion, computational binding models, and GPU compute architecture to advance this novel class of medicine.
With demonstrated success against multiple transmembrane receptor targets, DaX™ delivers remarkable drug development efficiency: design-build-test cycles in ~4 weeks with laboratory validated hit rates higher than current industry standards. The platform's sophisticated multi-objective optimization enables simultaneous refinement of key drug properties, including specificity, half-life, and solubility, transforming the scope and velocity of drug development.
Partner With Us
If you would like to learn more information about Mirror Peptides, our DaX™ platform, and partnering with Aizen, please reach out to us at partnering@aizentx.com.
Download a whitepaper on the history of Mirror Peptides (D-amino acids) in human therapeutics, and learn how Aizen’s Mirror Peptides can deliver clinical benefits to patients.